Hwan Geun Choi

This inventor holds 53 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Kinase Inhibitors. Top assignees: Dana-Farber-Cancer Institute Inc., Korea Institute of Science and Technology, Daegu-Gyeongbuk Medical Innovation Foundation. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hwan Geun Choi. Retrieved from https://idiyas.com/inventor/hwan-geun-choi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 7)

% Patents Active = 79.2

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 5.5

ph-index = 9

Forward Citations = 314(Granted Patents)

Forward Citations (Not Self Cited) = 243(Dec 10, 2025)

Location History:

Seoul, KR (2012 - 2022)
Chestnut Hill, MA (US) (2015 - 2023)
Daegu, KR (2019 - 2023)

Company Filing History:

32 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

11 out of 2,248

Korea Institute of Science and Technology

patents

5 out of 10

Daegu-Gyeongbuk Medical Innovation Foundation

patents

4. 5 out of 3,073

The General Hospital Corporation

patents

5. 4 out of 486

The Broad Institute, Inc.

Hanmi Science Co., Ltd.

patents

8. 2 out of 334

Korea Research Institute of Bioscience and Biotechnology

Catholic University Industry Academic Cooperation Foundation

patents

11. 1 out of 274

Daegu Gyeongbuk Institute of Science and Technology

patents

12. 1 out of 148

Hanmi Pharm. Co., Ltd.

Immunoforge Co., Ltd.

patent

15. 1 out of 654

Korea Research Institute of Chemical Technology

National Cancer Center

patents

18. 1 out of 145

Samsung Life Public Welfare Foundation

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

EGFR Inhibitors

Protein Kinase

SIK Inhibitors

Heteroaryl Derivative

Bicyclic Urea

Pyrimidines

Thiazolyl Compounds

Imidazolyl Kinase

Macrocyclic Kinase

Ras Inhibitors

Drug-Resistance

CML Therapeutics

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760013 - Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient (2026-10-13),

2. 12673945 - 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethinyl)-n-phenylbenzamide derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer (2026-07-07),

3. 12331037 - Pyrimidines as EGFR-inhibitors and methods of treating disorders (2025-06-17),

4. 12157730 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-12-03),

5. 12152021 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-11-26),

6. 11826365 - Type II raf kinase inhibitors (2023-11-28),

7. 11725011 - Bicyclic urea kinase inhibitors and uses thereof (2023-08-15),

8. 11673882 - Pyrimidines as EGFR inhibitors and methods of treating disorders (2023-06-13),

9. 11466000 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2022-10-11),

10. 11447480 - Compound exhibiting enteropeptidase inhibitory activity (2022-09-20),

11. 11285158 - Uses of pyrimidopyrimidinones as SIK inhibitors (2022-03-29),

12. 11241435 - Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis (2022-02-08),

13. 11208412 - Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease (2021-12-28),

14. 11117892 - Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases (2021-09-14),

15. 10975058 - Imidazolyl kinase inhibitors and uses thereof (2021-04-13),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with a detailed article about inventor Hwan Geun Choi based on the data you have provided. Here is the structured article:

Title: The Innovations and Impact of Inventor Hwan Geun Choi

Introduction:

Hwan Geun Choi, a prolific inventor hailing from Seoul, South Korea, has garnered recognition for his groundbreaking work in the field of pharmaceuticals and kinase inhibitors. With an impressive portfolio of 48 patents to his name, Choi has made significant contributions to the medical industry through his innovative research and discoveries.

Latest Patents:

Choi's latest patents showcase his expertise in developing novel compounds for the treatment of various diseases. One of his recent inventions includes Type II Raf kinase inhibitors, focusing on modulating B-raf kinases to address a range of medical conditions. Additionally, his work on bicyclic urea kinase inhibitors demonstrates the potential to inhibit protein kinases like SIK, offering new possibilities for treating a diverse array of diseases and disorders.

Career Highlights:

Throughout his career, Hwan Geun Choi has made substantial strides in his field, primarily working with esteemed organizations such as the Dana-Farber Cancer Institute Inc. and the Korea Institute of Science and Technology. His dedication to research and development has paved the way for innovative pharmaceutical solutions that have the potential to revolutionize the healthcare industry.

Collaborations:

Choi's collaborative efforts with accomplished coworkers, including Nathanael Schiander Gray and Tae Bo Sim, have further enriched his contributions to the scientific community. By working alongside talented individuals, he has been able to exchange ideas, drive innovation, and push the boundaries of scientific discovery.

Conclusion:

In conclusion, Hwan Geun Choi stands out as a visionary inventor whose relentless pursuit of excellence has led to the creation of groundbreaking pharmaceutical compounds and kinase inhibitors. His impact on the field of medicine is undeniable, and his patents serve as a testament to his ingenuity and commitment to improving healthcare solutions for individuals worldwide.

Profile summary based on public USPTO records.